MARKHAM, Ontario, Aug. 28, 2017 -- MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.
MedReleaf’s CEO, Neil Closner, is scheduled to present on Wednesday, September 6 at 3:30 p.m. Pacific time, with one-on-one meetings held throughout the conference.
The presentation will be webcast live and available for replay in the Investor Relations section of MedReleaf’s website at http://investors.medreleaf.com/ or on the Gateway Conference website at www.gateway-conference.com/presenters.
To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected].
About the Gateway Conference
The 6th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
Investor Contact: Dennis Fong, Investor Relations, [email protected], (416) 283-9930


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Instagram Outage Disrupts Thousands of U.S. Users
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 



